FindTrial
Sign In

An open label randomised controlled study to compare role of amitriptyline versus propranolol in treatment of migraine with calcified neurocysticercosis

Role of amitriptyline versus propranolol in treatment of migraine with calcified neurocysticercosis - an open label randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052791
Enrollment
120
Registered
2023-05-17
Start date
Unknown
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G439- Migraine, unspecified

Interventions

Intervention1: Amitriptyline: will initially receive amitriptyline 10mg at night for 7 days and then the dose will be increased to 25mg at night for rest of the study. Intervention2: Propranolol: wil

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients presented with migraine according to ICHD 3 criteria 2) NCCT HEAD showing calcified granuloma

Exclusion criteria

Exclusion criteria: 1) Patients who are a k/c/o asthma and ecg s/o AV block or bradycardia. 2)Patients with seizures. 3)Patients refusing consent. 4)Patients already on preventive medications

Design outcomes

Primary

MeasureTime frame
We will compare change in headache frequency between the two groups at the end of 1st, 2nd and 3rd months. Timepoint: 1st, 2nd and 3rd months.—

Secondary

MeasureTime frame
We will also compare severity of headache [VAS ] and disability caused by headache [ HIT6] between the two groups at the end of 1st, 2nd and 3rd months. Timepoint: 1st, 2nd and 3rd months—

Countries

India

Contacts

Public ContactDr Ravi Uniyal

KGMU

ravi.sun.uniyal@gmail.com6307043508

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026